Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Navidea Biopharma (NAVB) Tops Q4 EPS by 1c, Revenues Miss
March 24, 2021 4:23 PM EDTNavidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.11), $0.01 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $219.25 thousand versus the consensus estimate of $600 thousand.
Michael Rosol, Ph.D., Chief Medical Officer for Navidea, said, The clinical research team is... More
